Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 3/20 | 0.37 |
| ▸ | BCR | P11274 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25128598 | 0.79 | MEN1 (0.39) | ABL1BCRMEN1KMT2ARPS6KA5 | |
| SCHEMBL12413633 | 0.78 | GLP1R (0.34) | RPS6KA5KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL16608045 | 0.77 | PDK2 (0.34) | — | |
| SCHEMBL12963737 | 0.76 | MBOAT4 (0.34) | — | |
| SCHEMBL16248184 | 0.75 | S100A9 (0.33) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL12413632 | 0.75 | SMN1; SMN2 (0.42) | KMT2ARPS6KA5KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL31722144 | 0.75 | P2RX3 (0.40) | — | |
| SCHEMBL29038044 | 0.75 | GABRA1 (0.30) | — | |
| SCHEMBL558803 | 0.75 | P2RX3 (0.40) | — | |
| SCHEMBL10220470 | 0.72 | GAA (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257367-A1 | NOVEL THYROID HORMONE BETA RECEPTOR AGONIST | CHENGDU KANGHONG PHARMACEUTICAL CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230257367-A1 | NOVEL THYROID HORMONE BETA RECEPTOR AGONIST | CHENGDU KANGHONG PHARMACEUTICAL CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| EP-4159723-A1 | NOVEL THYROID HORMONE ß RECEPTOR AGONIST | Chengdu Kanghong Pharmaceutical Co., Ltd. (CN) | 2023-04-05 | — | — | EP | disclosed |
| EP-4076459-A1 | PRMT5 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2022-10-26 | — | — | EP | disclosed |
| EP-4007578-A1 | SUBSTITUTED CYCLOPROPYL-2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | Arbutus Biopharma, Inc. (US) | 2022-06-08 | — | — | EP | disclosed |
| WO-2021126728-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021025976-A1 | SUBSTITUTED CYCLOPROPYL-2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA, INC. (US) | 2021-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257367-A1 | NOVEL THYROID HORMONE BETA RECEPTOR AGONIST | THRB, THRA, TSHR | ABL1 4458/4885BCR 3208/4885MEN1 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.